SCHEMBL1010861

SCHEMBL1010861

CC(C)(Oc1ccc(CCNc2nc3ccccc3o2)cc1)C(=O)O

nearest known ligand 0.58

Predicted protein targets (top 11)

geneUniProtsupporting neighboursconfidence
PPARA Q07869 12/20 0.58
PPARG P37231 12/20 0.58
PPARD Q03181 3/20 0.58
KDM4E B2RXH2 1/20 0.53
MAPT P10636 1/20 0.53
ADRB3 P13945 3/20 0.51
HDAC6 Q9UBN7 1/20 0.50
ELANE P08246 1/20 0.47
ALDH1A1 P00352 1/20 0.47
FABP2 P12104 1/20 0.47
SMN1; SMN2 Q16637 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6544189 0.89 PPARG (0.47) PPARAPPARGPPARDKDM4EMAPT
SCHEMBL6543036 0.84 PPARA (0.57) PPARAPPARGPPARDKDM4EMAPT
SCHEMBL1010511 0.83 HDAC6 (0.43) PPARAPPARGPPARDKDM4EHDAC6
SCHEMBL2436469 0.83 PPARG (0.63) PPARAPPARGPPARDHDAC6
SCHEMBL6544080 0.82 PPARA (0.57) PPARAPPARGPPARDKDM4EMAPT
SCHEMBL6543171 0.81 PPARA (0.56) PPARAPPARGPPARDKDM4EMAPT
SCHEMBL2438034 0.81 PPARA (0.58) PPARAPPARGPPARDKDM4EMAPT
SCHEMBL6544125 0.80 PPARA (0.53) PPARAPPARGPPARDKDM4EMAPT
SCHEMBL6543344 0.80 PPARA (0.57) PPARAPPARGPPARDKDM4EMAPT
SCHEMBL6542975 0.80 PPARA (0.58) PPARAPPARGPPARDHDAC6ELANE

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1661890-B1 PPAR-ACTIVATING COMPOUND AND PHARMACEUTICAL COMPOSITION CONTAINING SAME KOWA CO (JP) 2011-01-05 EP disclosed
US-7183295-B2 PPAR-activating compound and pharmaceutical composition comprising the compound KOWA CO., LTD. (JP) 2007-02-27 US disclosed
US-7109226-B2 PPAR-activating compound and pharmaceutical composition comprising the compound KOWA CO., LTD. (JP) 2006-09-19 US disclosed
US-20060189667-A1 PPAR-activating compound and pharmaceutical composition comprising the compound KOWA CO., LTD. (JP) 2006-08-24 US disclosed
EP-1661890-A1 PPAR-ACTIVATING COMPOUND AND PHARMACEUTICAL COMPOSITION CONTAINING SAME Kowa Co., Ltd. (JP) 2006-05-31 EP disclosed
US-20050101636-A1 PPAR-activating compound and pharmaceutical composition comprising the compound KOWA CO., LTD. (JP) 2005-05-12 US disclosed
EP-1433786-A1 Benzoxazole compound and pharmaceutical composition containing the compound Kowa Company Ltd. (JP) 2004-06-30 EP disclosed
US-6653334-B1 Electively activate peroxisome proliferator activated receptors KOWA CO., LTD. (JP) 2003-11-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060189667-A1 PPAR-activating compound and pharmaceutical composition comprising the compound PPARA, PPARG, PPARD PPARA 1/4885PPARG 2/4885PPARD 3/4885
US-20050101636-A1 PPAR-activating compound and pharmaceutical composition comprising the compound PPARG, PPARA, PPARD PPARA 2/4885PPARG 1/4885PPARD 3/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.